NEW YORK (AP) — Shares of Ziopharm Oncology Inc. climbed Tuesday morning after the drug developer said it will go ahead with data analysis from a late-stage trial of its lead product, the potential cancer treatment palifosfamide.

The New York company said the study of palifosfamide as a treatment for patients with soft tissue sarcoma, which is a cancer that forms in connective tissue, reached enough progression-free survival events to complete data collection and then analysis.

Progression-free survival measures the time before a disease progresses or the patient in the study dies. The study measures how patients taking the drug fare compared to a control group.

Ziopharm will announce initial results from the study in late March. The company, which focuses on developing cancer treatments, has no other products on the market. It also is studying palifosfamide in a late-stage trial for a form of lung cancer and is developing an oral capsule form of the intravenous drug.

Shares climbed 14 percent, or 56 cents, to $4.55 at the start of trading Tuesday. The shares have ranged in price from $3.36 to $6.33 over the past year.

About News.net

Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.

 

FAQs

Email

If you have any questions or concerns please email us on support@news.net

Phone

  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.

Cancel